Skip to main content
. 2017 Aug 9;7:7671. doi: 10.1038/s41598-017-08110-x

Figure 5.

Figure 5

PDK1 inhibition protects FVB PrP0/0 mice from sTNFα-induced inflammation. (a) Measure of PDK1 activity indicating a rise of PDK1 activity in the brain of 20-weeks old FVB PrP0/0 mice compared to FVB wild type mice (n = 6 for each group). Values are means ± SEM. *p < 0.01 vs. FVB mice. (b) Concentration of sTNFR1 in the CSF of 20 weeks-old FVB PrP0/0 and wild type mice intracerebroventricular (icv) injected or not with the PDK1 inhibitor BX912 (n = 6 for each group). Values are means ± SEM. *p < 0.01 vs. nontreated FVB mice. **p < 0.01 vs. nontreated FVB PrP0/0 mice. (c) [kynurenine]/[tryptophan] ratio in the CSF of 20 weeks-old FVB PrP0/0 and wild type mice icv injected or not with BX912 following a sTNFα challenge (200 ng in 10 µl saline buffer) for 24 h (n = 6 for each group). Values are means ± SEM. *p < 0.01 vs. mice nontreated with sTNFα. # p < 0.01 vs. FVB mice treated with sTNFα. **p < 0.01 vs. sTNFα-treated mice.